Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Non-Current Deffered Revenue (2016 - 2017)

Amphastar Pharmaceuticals (AMPH) has 5 years of Non-Current Deffered Revenue data on record, last reported at $1.2 million in Q3 2017.

  • For Q3 2017, Non-Current Deffered Revenue rose 623.21% year-over-year to $1.2 million; the TTM value through Sep 2017 reached $1.2 million, up 623.21%, while the annual FY2016 figure was $97000.0, 92.76% down from the prior year.
  • Non-Current Deffered Revenue reached $1.2 million in Q3 2017 per AMPH's latest filing, up from $423000.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $2.6 million in Q4 2013 and bottomed at $97000.0 in Q4 2016.
  • Average Non-Current Deffered Revenue over 5 years is $1.3 million, with a median of $1.3 million recorded in 2015.
  • Peak YoY movement for Non-Current Deffered Revenue: tumbled 92.76% in 2016, then soared 623.21% in 2017.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $2.6 million in 2013, then fell by 24.5% to $2.0 million in 2014, then plummeted by 32.44% to $1.3 million in 2015, then crashed by 92.76% to $97000.0 in 2016, then skyrocketed by 1152.58% to $1.2 million in 2017.
  • Per Business Quant database, its latest 3 readings for Non-Current Deffered Revenue were $1.2 million in Q3 2017, $423000.0 in Q2 2017, and $280000.0 in Q1 2017.